Abiliti™ Treatment in Obese Subjects
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of this post-market surveillance study is to compare the subject's weight loss and quality of life, and device safety performance of the abiliti System and the adjustable gastric banding therapies in obese to morbidly obese subjects.
| Condition | Intervention |
|---|---|
|
Obesity Morbid Obesity |
Device: abiliti system implant Device: Laparoscopic adjustable gastric band (Allergan Lap Band) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Abiliti™ Treatment in Obese Subjects: A Randomized Post-Market Surveillance Multicenter Study |
- Non-inferiority of the abiliti therapy compared to adjustable gastric banding [ Time Frame: 12 months ] [ Designated as safety issue: No ]
The non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria:
- Achieve at least 20% excess weight loss (%EWL) from implant to end of the study period.
- Experience no serious or severe adverse events related to the device or the procedure
- No significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)
- Percentage of Responders [ Time Frame: 12 months ] [ Designated as safety issue: No ]Fifty (50 %) of the subject population must obtain an EWL ≥ 25%
- Safety [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Incidence and seriousness of all adverse events.
- Incidence of device or procedure-related adverse events
- Frequency of clinically significant abnormal laboratory values as determined by the Investigator;
- Safety [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]Frequency of device and procedure-related adverse events
- Quality of Life [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]Change in the quality of life using the IWQOL-Lite questionnaire
- Eating Behavior [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]Change in the eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ).
- Co-morbid Conditions [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]Evaluation of the changes in blood pressure, lipid panel, HbA1c
| Estimated Enrollment: | 165 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | January 2015 |
| Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: abiliti Group
Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
|
Device: abiliti system implant
Subjects will receive implanted abiliti System.
Other Name: abiliti
|
|
Active Comparator: Gastric Band Group
Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
|
Device: Laparoscopic adjustable gastric band (Allergan Lap Band)
Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
Other Name: gastric band
|
Detailed Description:
This study is intended to provide additional data regarding the performance and safety of the abiliti system in comparison to gastric banding. The composite end-point of the study is designed to provide a direct comparison of the effectiveness of the devices for the treatment of obesity while giving consideration to the safety profile for each device and their impact on patient quality of life.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age of 18 - 60 years old at time of screening
- BMI of 40 to 55 or 35 to 39 with an obesity related comorbid condition at time of screening
- History of obesity ≥5 years
- The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
- Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
- No significant weight loss (<5%) within four months prior to enrollment as documented in the subject's medical record.
- Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment.
- Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment.
- If taking anti-depressant medications, they must be stable for at least six months prior to enrollment
- Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
- Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
- Able to provide voluntary informed consent
Exclusion Criteria:
- Any prior bariatric surgery
- Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
- Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures
- Use of anti-psychotic medications
- Diagnosed with a eating disorder such as bulimia or binge eating
- Obesity due to an endocrinopathy (e.g. Cushing disease)
- Insulin therapy
- GI disease such as hiatal hernia (>5cm), gastroparesis, esophageal motility disorders or intractable constipation.
- Cirrhosis, chronic pancreatitis
- History of intestinal obstruction or adhesive peritonitis
- Any history of peptic ulcer disease within 5 years prior to enrollment
- Women who are pregnant, lactating or anticipate becoming pregnant within 24 months
- Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study.
- Chronic use of aspirin and/or non steroidal anti-inflammatory medications and unwillingness to discontinue use
- Cardiac history that physician feels should exclude the patient from the study.
- Concurrent use of weight loss medications.
- Use of another investigational device or agent in the 30 days prior to enrollment
- A history of life-threatening disease within 5 years prior to enrollment
- Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study
Contacts and Locations| Contact: Robert Nardelli | 650-316-4065 |
| France | |
| Polyclinique de Rillieux, Clinique Lyon-Nord | Recruiting |
| RILLIEUX Cedex, France, 69165 | |
| Contact: Jerome Dargent, MD | |
| Principal Investigator: Jerome Dargent, MD | |
| Germany | |
| MIC Ev. Krankenhaus Hubertus | Recruiting |
| Berlin, Germany, 14129 | |
| Contact: Martin Susewind, MD | |
| Principal Investigator: Martin Susewind, MD | |
| SRH Wald-Klinikum Gera | Recruiting |
| Gera, Germany, 07548 | |
| Contact: Christine Stroh, MD | |
| Principal Investigator: Christine Stroh, MD | |
| Wolfart Klinik | Active, not recruiting |
| Graefelfing, Germany, 92166 | |
| Universitätsklinikum Hamburg-Eppendorf | Recruiting |
| Hamburg, Germany, 20246 | |
| Contact: Oliver Mann, MD | |
| Principal Investigator: Oliver Mann, MD | |
| Stadtkrankenhaus Schwabach | Recruiting |
| Schwabach, Germany, 91126 | |
| Contact: Thomas Horbach, MD | |
| Principal Investigator: Thomas Horbach, MD | |
| Italy | |
| Azienda Ospedaliera- University | Not yet recruiting |
| Pisa, Italy | |
| Contact: Marco Anselmino, MD | |
| Principal Investigator: Marco Anselmino, MD | |
| Clinica San Luca Torino | Not yet recruiting |
| Turin, Italy | |
| Contact: Giuseppe M Rovera, MD | |
| Principal Investigator: Giuseppe M Rovera, MD | |
| Vicenza Regional Hospital | Not yet recruiting |
| Vicenza, Italy, 36100 | |
| Contact: Franco Favretti, MD | |
| Principal Investigator: Franco Favretti, MD | |
| Spain | |
| Complutense University of Madrid Hospital Clinico "San Carlos" | Not yet recruiting |
| Madrid, Spain, 28290 | |
| Contact: Antonio J Torres, MD | |
| Principal Investigator: Antonio J Torres, MD | |
| Hospital Virgen del Roció | Recruiting |
| Sevilla, Spain, 41013 | |
| Contact: Salvador Morales Conde, MD | |
| Principal Investigator: Salvador Morales Conde, MD | |
| Switzerland | |
| Klinik Lindberg | Recruiting |
| Winterthur, Switzerland, 8400 | |
| Contact: Fritz Horber, MD | |
| Principal Investigator: Fritz Horber, MD | |
| United Kingdom | |
| Spire Southampton Hospital | Not yet recruiting |
| Hampshire, Southampton, United Kingdom, SO16 6UY | |
| Contact: James Byrne, MD | |
| Principal Investigator: James Byrne, MD | |
| St. Anthony's Hospital | Not yet recruiting |
| North Cheam, Surrey, United Kingdom, SM3 9DW | |
| Contact: Alberic Fiennes, MD | |
| Principal Investigator: Alberic Fiennes, MD | |
| Mid Yorkshire NHS Trust | Not yet recruiting |
| Dewsbury, West Yorkshire, United Kingdom, WF13 4HS | |
| Contact: Chinnadorai Rajeswaran, MD | |
| Principal Investigator: Chinnadorai Rajeswaran, MD | |
| Principal Investigator: | Thomas Horbach, MD | Stadtkrankenhaus Schwabach |
| Principal Investigator: | Alberic Fiennes, MD | St Anthony's Hospital, Surrey, England |
More Information
No publications provided
| Responsible Party: | IntraPace, Inc |
| ClinicalTrials.gov Identifier: | NCT01448785 History of Changes |
| Other Study ID Numbers: | CS-007-P |
| Study First Received: | October 3, 2011 |
| Last Updated: | October 27, 2011 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices United Kingdom: National Health Service Italy: Ministry of Health Spain: Spanish Agency of Medicines Switzerland: Swissmedic |
Keywords provided by IntraPace, Inc:
|
obesity gastric stimulation morbid obesity |
Additional relevant MeSH terms:
|
Obesity Obesity, Morbid Overnutrition Nutrition Disorders |
Overweight Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013